SEHK:2268Life Sciences
Will Repeat Ona Licensing Change WuXi XDC Stock Narrative
WuXi XDC Cayman announced that Ona Therapeutics has obtained an exclusive global license to the WuXiTecan-2 payload-linker platform for one antibody drug conjugate, with WuXi XDC also providing chemistry, manufacturing and controls support plus potential upfront, milestone and royalty revenues.
The new out-licensing deal, the second ADC collaboration between WuXi XDC and Ona in two years, points to recurring client demand for WuXi XDC’s proprietary linker payload capabilities and deeper...